ArticleOphthalmology and therapy2026
Prediction Models for Recurrence of Retinopathy of Prematurity after Intravitreal Ranibizumab or Laser Photocoagulation Treatment: A Multicenter Cohort Study.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionTo develop prediction models for retinopathy of prematurity (ROP) recurrence after initial intravitreal injection of ranibizumab (IVR) or laser photocoagulation (LP).
methodsThis multicenter retrospective cohort study included infants with aggressive posterior ROP (AP-ROP) and type-I ROP. Recurrence was defined as the reappearance of vascular dilation, tortuosity, or new/recurrent neo-vascularization in either eye of infants. The recurrence rates within 6 months after initial treatment were compared. Machine learning (i.e., extreme gradient boost, categorical boost, adaptive boost, and random forest) and multivariable logistic regression were performed to identify risk factors and establish individualized prediction models for ROP recurrence. Area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity were used to evaluate the performance of the prediction models.
resultsA total of 440 infants were included, with a mean gestational age (standard deviation [SD]) of 28.2 (2.4) weeks and birth weight (SD) of 1.1 (0.4) kg. ROP recurrence occurred in 62 of 344 (18.0%) infants after IVR treatment, while 7 of 96 (7.3%) infants after LP treatment required additional treatment (P < 0.05). Neonatal pneumonia, respiratory distress, septicemia, 5-min Apgar scoring, AP-ROP, and maternal uterine infection were significantly associated with the risk of ROP recurrence (all P < 0.05). The Categorical Boost model achieved the best overall performance. The mean AUC, accuracy, sensitivity, and specificity were 0.96 (95% confidence interval [CI] 0.93-0.99), 85.9% (95% CI 80.3-91.5%), 94.7% (95% CI 89.6-99.8%), and 77.0% (95% CI 67.4-86.6%) on the validation dataset, and 0.94 (95% CI 0.89-1.00), 84.1% (95% CI 77.1-93.2%), 95.5% (95% CI 89.8-100%), and 72.7% (95% CI 59.6-85.5%) on the testing dataset, respectively.
conclusionThis study presents a simple, rapid, and reliable predictive strategy for early identifying infants at high risk of ROP recurrence after initial treatment, which is potentially useful in improving the success rate of retreatment and reducing blindness resulting from ROP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.